Trial
NCT00040144
Safety and Antiviral Study of ACH126, 433 (b-L-Fd4C) in Adults With Lamivudine-resistant Chronic Hepatitis B
Phase IITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
Alexion Pharmaceuticals, Inc.
Collaborators
Achillion, a wholly owned subsidiary of Alexion
Condition
Chronic Hepatitis B
Intervention
ACH126, 433
Why stopped
Safety concerns
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-02-18